Abingdon Health is a British manufacturer of lateral flow assay diagnostic tests, sometimes called rapid tests, lateral flow immunoassays (LFIA), lateral flow tests (LFT) or quick tests. Since its formation in 2008, the Company has grown to become an organisation of over 200 people and has developed and manufactured lateral flow rapid tests across multiple industries.
Headquartered in York UK, the company offers lateral flow product research and development, regulatory support, technical transfer and manufacturing.
Having previously worked with Abingdon Health and their advisers N+1 Singer (now Singer Capital Markets) with the production of their admission document when they floated on AIM in December last year, the Perivan shareholder communications team were delighted to help them with a further stage of their corporate journey by designing and producing their inaugural annual report which was successfully published on 29th November 2021.
To view the full annual report, click here.
Perivan specialise in the production and publication of financial documents relating to shareholder and investor communications for quoted companies, private companies and open and closed-ended funds.